Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Center for International Blood and Marrow Transplant Research
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Center for International Blood and Marrow Transplant Research
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
City of Hope Medical Center
St. Jude Children's Research Hospital
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
University of Virginia
Universitätsklinikum Hamburg-Eppendorf
Otsuka Beijing Research Institute
Gruppo Italiano Malattie EMatologiche dell'Adulto
Stichting Hemato-Oncologie voor Volwassenen Nederland
Institut d'Investigacions Biomèdiques August Pi i Sunyer
University of Birmingham
Assistance Publique - Hôpitaux de Paris